Introduction
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by breakdown of immune tolerance and production of several autoantibodies. 1 The role of T-cells in the pathogenesis of the disease includes not only their participation in the processes of B-cell proliferation and class switch recombination, with enhancement of the production of autoantibodies, but also other phenotypic and functional alterations: among these, T-cell receptor signal modifications, quantitative and/or qualitative defects of T-regulatory (TREG) mechanisms, cytokine imbalance and expansion of Th17 subpopulation have been described. 1, 2 Phenotypic characterization of the TREG and the T-cell effector populations may therefore provide information on the status of the T-cell compartment and its participation in SLE disease processes. However, few studies have investigated the T-cell effector populations in SLE patients, and not much information is available regarding the possible correlation between these T-cell subsets and SLE activity and damage indexes.
For this purpose, we took advantage of the well-characterized phenotypic modiEcations of Tcells induced by antigen stimulation. First, naı¨ve CD45RAþ T-cells undergo CD45RA down-modulation. Then, memory CD45RAÀ T-cells can be characterized by the expression of the chemokine receptor CCR7. 3 In fact, loss of CCR7 contributes to the migration from lymphoid organs to the periphery.
3 CCR7 þ CD45RAÀ T-cells are therefore believed to represent the central memory (CM) subset, migrating preferentially to the T-cell areas of lymphoid organs and having only minimal cytokine-secreting capacity. On the other hand, CCR7 À CD45RAÀ T-cells are thought to represent the effector memory (EM) subset, having acquired different migratory capabilities and effector functions, such as cytokine production or cytotoxicity, which they can exert after their migration to inflamed peripheral tissues. 4 Moreover, CD45RA may be re-expressed as a consequence of repeated stimulation. T-cells with CD45RA þ CCR7À phenotype are therefore known as ''terminally differentiated effector memory'' (TDEM) T-cells. Finally, the costimulatory receptor CD28, constitutively present on all naı¨ve T-cells (CCR7 þ CD45RAþ), may also be down-modulated after repeated stimuli. The final result of the perpetual immune system activation is the oligoclonal expansion of T-cells characterized by CD45RA þ CCR7À and CD28À phenotype. These CD28À TDEM T-cells are distinguished by peculiar features, such as resistance to apoptosis and low capability for proliferation. 5 The aim of this study was to evaluate the phenotype of circulating T-cell subsets in a cohort of SLE patients, comparing it with a group of healthy subjects and correlating it with other disease characteristics.
Methods

Patients
Between May 2011 and July 2016, 51 SLE patients (3 males, 48 females; median age (10th-90th percentile) 35 (24-44) years old) were enrolled at the Department of Rheumatology and Clinical Immunology in Brescia, Italy. They were classified according to the revised American College of Rheumatology (ACR) criteria, 6 and their main clinical, laboratory and demographical features, obtained from clinical charts, are presented in Table 1 . The study was approved by the local institutional ethics committee and conducted in accordance with the Declaration of Helsinki. In 18 patients the sample was collected before the infusion of the first dose of belimumab. The entire cohort of SLE patients was divided according to disease activity, determined by SLE Disease Activity Index-2000 (SLEDAI-2K), and disease damage, assessed with the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index (SDI). 7, 8 A SLEDAI-2K index below 6 defined a population with low disease activity (n ¼ 38), whereas an index value above or equal to 6 identified a population with high disease activity (n ¼ 13). 7 Furthermore, 21 sex-and age-comparable healthy donors (2 males, 19 females; median age 40 (28-53) years old) were enrolled as a control group for T-cell immunophenotype comparison.
Flow cytometry
Peripheral blood samples were used for phenotypic study of T-cells. Lymphocyte surface markers were evaluated by Fow cytometry (Cytomics NAVIOS, Beckman Coulter Inc., Fullerton, CA, USA), using monoclonal antibodies conjugated with Fuorochromes (Beckman Coulter) to identify lymphocyte subpopulations. A sample of 100 mL of whole blood was stained for 30 minutes at 4 C with FITC-CCR7, PE-CD45RA, ECD-CD28, PC5-CD3 and PC7-CD8. In a second tube, PE-CD25, PC5-CD4 and PC7-CD127 were used to evaluate TREGs, defined as CD4 þ CD127lowCD25high T-cells (Supplementary Figure 1) . Absolute cell counts were determined by single platform analysis using Flow-Count beads (Beckman Coulter).
Statistical analysis
The variations between different groups were evaluated by Mann-Whitney test. Chi-square test or Fisher's exact test was applied for comparison between qualitative variables, as appropriate. Bonferroni correction was applied to adjust for multiple comparisons (adjusted p: p adj ). However, Bonferroni correction assumes that all tests are independent of each other, which is clearly not the case in our study. Therefore, it increases the probability of producing type II errors. We decided therefore to present also unadjusted p values (p) as indicators of possible trends towards differences. Spearman rank test was used to evaluate the correlations between quantitative variables. Statistical analysis was performed using the software package StatView (SAS Institute Inc., Cary, NC, USA).
Results
Features of patients of different groups
There were no differences between SLE patients with low and high disease activity in their demographic, clinical and laboratory features, except for anti-dsDNA and complement fraction 3 levels (Table 1) . Most patients with a high disease activity required belimumab therapy, but blood samples for T-cell phenotypic analysis were taken before the administration of the first dose of the drug.
Twelve patients had a SDI ! 1: four had cataract, three deforming arthritis, one muscle atrophy, one scarring chronic alopecia, two valvular disease, one chronic pericarditis, and two cerebrovascular accident. No demographic, clinical or laboratory difference was found between patients with and without SDI ! 1 (data not shown).
Phenotypic analysis of T-cells. Comparison between SLE patients and healthy controls
As shown in Table 2 , the absolute number of total CD4þ T-cells was significantly lower among SLE patients than in healthy controls (p adj ¼ .004), and a similar trend was observed for total CD8þ T-cells
The analysis of T-cell subsets showed a trend towards an increased percentage of TDEM among CD4þ T-cells in SLE patients (p ¼ .04). Considering CD8þ T-cells, there was a significant Effector T-cells are expanded in active SLE S Piantoni et al.
Table 2
Comparisons among the number of T-cell subsets (expressed as percentage and absolute number) between patients and healthy controls (a), between patients with low and high disease activity (b) and between patients with and without SDI !
(c)
T-cell phenotype Healthy controls .66
CD8þ CM (% CD8þ) 6 (2-11)
.0004
.0028
.06
.15
CD8þ CM (cell/mL) .27
CD8þ EM (% CD8þ) 
Phenotypic analysis of T-cells. Comparison among SLE patients according to disease activity and damage
As shown in Table 2 , in patients with high disease activity there was a trend towards a lower absolute number of total circulating CD4þ (p ¼ .10) and CD8þ T-cells (p ¼ .09) compared with patients with lower activity.
The analysis of CD4þ T-cell subsets showed, in patients with SLEDAI-2K ! 6 as compared with other SLE patients, increased percentages of EM (p adj ¼ .004), TDEM (p adj ¼ .002) and CD4 þ CD28À T-cells (p adj ¼ .005). Vice versa, percentages of CM T-cells were lower among CD4þ T-cells in patients with high disease activity (p adj ¼ .001), and there was a trend towards a lower percentage of TREGs (p ¼ .02).
A similar trend was observed among CD8þ T-cells, with an increased percentage of TDEM in patients with SLEDAI-2K ! 6 (p ¼ .06). In contrast, naı¨ve and CM CD8þ T-cells tended to be more represented in patients with lower disease activity (p ¼ .03 and p ¼ .06, respectively).
When the cohort is divided according to damage, patients with SDI!1 tended to show an expansion of TDEM CD4þ T-cells (p ¼ .01) and a reduction of CM CD4þ T-cells (p ¼ .03) in comparison with patients with SDI ¼ 0.
Phenotypic analysis of T-cells. Comparison among SLE patients according to concomitant therapies
Almost all patients were treated with prednisone (n ¼ 47), but no significant correlation was observed between prednisone dosage and cell populations. Moreover, there was no significant difference in cell population distribution between patients in therapy with (n ¼ 30) and without (n ¼ 21) immunosuppressive drugs.
Correlations between T-cell populations in SLE patients
An inverse correlation between the percentages of TREGs and those of CD4 þ TDEM (p < .01) and CD4 þ CD28À (p < .01) T-cells was found among SLE patients (Figure 1 ).
Discussion
Innate and adaptive immunity are both involved in the pathogenesis of SLE, and recent evidence has underlined the central role of T-cells. 1 In our cohort, a reduction of circulating T-cells (particularly of CD4þ cells) in comparison with healthy controls was observed, and this tended to be more severe in the group of patients with higher disease activity. Lymphopenia is a common clinical manifestation in SLE and is one of the classification criteria. 6 Our data are consistent with reports demonstrating the association between lymphopenia and high SLE disease activity index.
9 CD4þ T-cell lymphopenia in SLE may be explained by different mechanisms, including the presence of anti-CD4 antibodies, frequently found in SLE patients, 10 and increased T-cell apoptosis in active SLE. 11 Moreover, the reduced expression of the CD28 molecule on the membrane may expose the lymphocytes to activation-induced cell death. 12 It is noteworthy, therefore, that an expansion of the subpopulation of CD4þCD28À T-cells has been described in a cohort of SLE patients in association with disease damage, but independently of age, gender, disease duration, disease activity, comorbidities and use of drugs, thus suggesting a possible role of these cells in SLE damage pathogenesis. 13 On the other hand, conflicting results have been reported regarding the CD28À population among CD8þ T-cells. While some authors reported that their number might be reduced or unchanged in SLE as compared with healthy subjects, 14 others found an increased number in patients with active lupus nephritis. 15 In our cohort we observed an expansion of CD4 þ CD28À T-cells among patients with higher disease activity, but no difference between the entire cohort of patients and healthy controls, or among patients with and without damage; no difference was found regarding CD8 þ CD28À T-cells. Considering that CD28À T-cells are the results of repeated antigen stimulation and that an increase in their number could be a marker of immunosenescence, 5 it cannot be excluded that the slightly higher median age of the control healthy subjects enrolled in our study, as compared with SLE patients, might mask a possible increase of the CD28À subset also among CD8þ T-cells in SLE. We could not confirm the possible role of CD28À T-cells in lupus nephritis, suggested by recent clinical studies; 13, 15 however, despite some patients suffering from renal involvement in their clinical history, none in our cohort had active nephritis or chronic renal damage.
A novel aspect of our study was the demonstration that effector T-cell subpopulations were expanded in the group of SLE patients with higher disease activity and, possibly, with higher damage index. These results are in accordance with previous reports demonstrating that CCR7À memory T-cells are increased in SLE. 4 These cells were also shown to have a decreased proliferative capacity and a strong inclination towards apoptosis in this disease. 4 Nevertheless, they are able to express high levels of interferon-gamma, granzyme B and perforin, thus potentially contributing to the chronic inflammation and resulting organ damage in SLE. The expansion of the effector/memory CCR7À subpopulations may reflect a process of chronic ongoing antigenic stimulation and the consequent increased cell replications 3 and/or may be the result of a weakened TREG compartment, with consequent increased response against self-antigens. 1 In accordance with this latter hypothesis, we have observed a trend towards a reduced number of circulating TREGs in patients with high disease activity. Conflicting results were previously reported on TREG populations in SLE. In fact, both quantitative and functional alterations were described, in correlation with serological parameters and/or clinical disease activity. However, the heterogeneous definition of this subpopulation in different studies makes it difficult to compare them; in particular, it has been suggested that FoxP3, which is considered the specific TREG transcription factor, may be expressed by T-cells other than TREGs in SLE patients. 1 In any case, the correlation between the decreased percentages of TREGs and the increased percentages of effector T-cells observed in our cohort of patients may support the hypothesis that these two events are strictly linked to each other, or that they result from a common mechanism.
Although it is not clear whether the hyper-activation of T-cells observed in patients with active SLE is caused by intrinsic abnormalities of effector T-cells, alterations of external influences, or both, our study is in agreement with the hypothesis of a prominent role of T-cells in SLE disease mechanisms. The potential role of these populations as biomarkers of chronic ongoing immune system activation and senescence warrants further studies.
